Histone deacetylase inhibition destabilizes the multi-potent state of uncommitted adipose-derived mesenchymal stromal cells

Journal of Cellular Physiology

Volumn 230, Issue 1, 2015, Pages 52-62

  Dudakovic, Amel ^a   Camilleri, Emily T ^a   Lewallen, Eric A ^a   Mcgee Lawrence, Meghan E ^a   Riester, Scott M ^a   Kakar, Sanjeev ^a   Montecino, Martin ^b   Stein, Gary S ^c   Ryoo, Hyun Mo ^d   Dietz, Allan B ^a   Westendorf, Jennifer J ^a,e   Van Wijnen, Andre J ^a,e  

^a MAYO CLINIC   (United States)

^b UNIVERSIDAD ANDRÉS BELLO   (Chile)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d Seoul National University   (South Korea)

^e MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PROTEIN KINASE B; RNA; SIRTUIN 1; TRANSCRIPTION FACTOR FKHR; VORINOSTAT; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; HISTONE; HYDROXAMIC ACID; PHOSPHOPROTEIN; SODIUM PROTON EXCHANGE PROTEIN; SODIUM-HYDROGEN EXCHANGER REGULATORY FACTOR;

ADIPOCYTE; ADIPOSE DERIVED STEM CELL; ARTICLE; CARTILAGE CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; MESENCHYMAL STROMA CELL; MINERALIZATION; OSTEOBLAST; PLURIPOTENT STEM CELL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; TISSUE REGENERATION; WESTERN BLOTTING; ACETYLATION; ADIPOSE TISSUE; BIOSYNTHESIS; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; METABOLISM; NUCLEOTIDE SEQUENCE; SEQUENCE ANALYSIS;

ACETYLATION; ADIPOCYTES; ADIPOSE TISSUE; BASE SEQUENCE; CELL DIFFERENTIATION; CELLS, CULTURED; CHONDROCYTES; FORKHEAD TRANSCRIPTION FACTORS; GUIDED TISSUE REGENERATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SEQUENCE ANALYSIS, RNA; SODIUM-HYDROGEN ANTIPORTER;

EID: 84910046421     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24680     Document Type: Article

References (47)

1. Aggarwal S, Pittenger MF. 2005. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822.
2. Boluk A, Guzelipek M, Savli H, Temel I, Ozisik HI, Kaygusuz A. 2004. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 50:93-97.
3. Bradley EW, Carpio LR, Westendorf JJ. 2013. Histone deacetylase 3 suppression increases PH domain and leucine-rich repeat phosphatase (Phlpp) 1 expression in chondrocytes to suppress Akt signaling and matrix secretion. J Biol Chem 288:9572-9582.
4. Bradley EW, Drissi MH. 2010. WNT5A regulates chondrocyte differentiation through differential use of the CaN/NFAT and IKK/NF-kappaB pathways. Mol Endocrinol 24:1581-1593.
5. Cobo F, Talavera P, Concha A. 2006. Diagnostic approaches for viruses and prions in stem cell banks. Virology 347:1-10.
6. Crespo-Diaz R, Behfar A, Butler GW, Padley DJ, Sarr MG, Bartunek J, Dietz AB, Terzic A. 2011. Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability. Cell Transplant 20:797-811.
7. Di Bernardo G, Squillaro T, Dell'Aversana C, Miceli M, Cipollaro M, Cascino A, Altucci L, Galderisi U. 2009. Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells. Stem Cells Dev 18:573-581.
8. Doerr HW, Cinatl J, Sturmer M, Rabenau HF. 2003. Prions and orthopedic surgery. Infection 31:163-171.
9. Dudakovic A, Evans JM, Li Y, Middha S, McGee-Lawrence ME, van Wijnen AJ, Westendorf JJ. 2013. Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces Akt phosphorylation. J Biol Chem 288:28783-28791.
10. Grunstein M. 1997. Histone acetylation in chromatin structure and transcription. Nature 389:349-352.
11. Haberland M, Carrer M, Mokalled MH, Montgomery RL, Olson EN. 2010. Redundant control of adipogenesis by histone deacetylases 1 and 2. J Biol Chem 285:14663-14670.
12. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. 2002. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 99:8932-8937.
13. Hu X, Zhang X, Dai L, Zhu J, Jia Z, Wang W, Zhou C, Ao Y. 2013. Histone deacetylase inhibitor trichostatin A promotes the osteogenic differentiation of rat adipose-derived stem cells by altering the epigenetic modifications on Runx2 promoter in a BMP signalingdependent manner. Stem Cells Dev 22:248-255.
14. Hutt DM, Herman D, Rodrigues AP, Noel S, Pilewski JM, Matteson J, Hoch B, Kellner W, Kelly JW, Schmidt A, Thomas PJ, Matsumura Y, Skach WR, Gentzsch M, Riordan JR, Sorscher EJ, Okiyoneda T, Yates JR, III , Lukacs GL, Frizzell RA, Manning G, Gottesfeld JM, Balch WE. 2010. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 6:25-33.
15. Iwami K, Moriyama T. 1993. Effects of short chain fatty acid, sodium butyrate, on osteoblastic cells and osteoclastic cells. Int J Biochem 25:1631-1635.
16. Jensen ED, Schroeder TM, Bailey J, Gopalakrishnan R, Westendorf JJ. 2008. Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J Bone Miner Res 23:361-372.
17. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. 2006. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24:1294-1301.
18. Kim HJ, Bae SC. 2011. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 3:166-179.
19. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. 2013. TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14:R36.
20. Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W. 2002. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 30:215-222.
21. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. 2004. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439-1441.
22. Lee S, Park JR, Seo MS, Roh KH, Park SB, Hwang JW, Sun B, Seo K, Lee YS, Kang SK, Jung JW, Kang KS. 2009. Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells. Cell Prolif 42:711-720.
23. Lee HW, Suh JH, Kim AY, Lee YS, Park SY, Kim JB. 2006. Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Mol Endocrinol 20:2432-2443.
24. Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, Russell SJ, Galanis E, Dietz AB, Peng KW. 2013. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med 11:20.
25. McGee-Lawrence ME, McCleary-Wheeler AL, Secreto FJ, Razidlo DF, Zhang M, Stensgard BA, Li X, Stein GS, Lian JB, Westendorf JJ. 2011. Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone 48:1117-1126.
26. McGee-Lawrence ME, Westendorf JJ. 2011. Histone deacetylases in skeletal development and bone mass maintenance. Gene 474:1-11.
27. Molina JR, Agarwal NK, Morales FC, Hayashi Y, Aldape KD, Cote G, Georgescu MM. 2012. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene 31:1264-1274.
28. Murphy MB, Moncivais K, Caplan AI. 2013. Mesenchymal stem cells: Environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 45:54.
29. Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U, Choong C, Yang Z, Vemuri MC, Rao MS, Tanavde V. 2008. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): Transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 112:295-307.
30. Nissen-Meyer LS, Svalheim S, Tauboll E, Reppe S, Lekva T, Solberg LB, Melhus G, Reinholt FP, Gjerstad L, Jemtland R. 2007. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 48:1850-1860.
31. Peterson CL, Laniel MA. 2004. Histones and histone modifications. Curr Biol 14:R546-R551.
32. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. 1999. Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
33. Pratap J, Akech J, Wixted JJ, Szabo G, Hussain S, McGee-Lawrence ME, Li X, Bedard K, Dhillon RJ, van Wijnen AJ, Stein JL, Stein GS, Westendorf JJ, Lian JB. 2010. The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther 9: 3210-3220.
34. Rafii S, Lyden D. 2003. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 9:702-712.
35. Robinson MD, McCarthy DJ, Smyth GK. 2010. EdgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26:139-140.
36. Schroeder TM, Kahler RA, Li X, Westendorf JJ. 2004. Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem 279:41998-42007.
37. Schroeder TM, Westendorf JJ. 2005. Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 20:2254-2263.
38. Senn SM, Kantor S, Poulton IJ, Morris MJ, Sims NA, O'Brien TJ, Wark JD. 2010. Adverse effects of valproate on bone: Defining a model to investigate the pathophysiology. Epilepsia 51:984-993.
39. Sheth RD, Wesolowski CA, Jacob JC, Penney S, Hobbs GR, Riggs JE, Bodensteiner JB. 1995. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 127: 256-262.
40. Soung do Y, Dong Y, Wang Y, Zuscik Y, Schwarz MJ, O'Keefe EM, Drissi RJ. 2007. Runx3/AML2/Cbfa3 regulates early and late chondrocyte differentiation. J Bone Miner Res 22:1260-1270.
41. Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, Hsu SC, Smith J, Prockop DJ. 2004. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 9:747-756.
42. Undale AH, Westendorf JJ, Yaszemski MJ, Khosla S. 2009. Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc 84:893-902.
43. Vestergaard P, Rejnmark L, Mosekilde L. 2004. Fracture risk associated with use of antiepileptic drugs. Epilepsia 45:1330-1337.
44. Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB, Yoshida M, Stein GS, Li X. 2002. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 22:7982-7992.
45. Wightman F, Ellenberg P, Churchill M, Lewin SR. 2012. HDAC inhibitors in HIV. Immunol Cell Biol 90:47-54.
46. Xu S, De Veirman K, Evans H, Santini GC, Vande Broek, Leleu I, De Becker X, Van Camp A, Croucher B, Vanderkerken P, Van Riet K. 2013. Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. Acta Pharmacol Sin 34:699-709.
47. Zaidi SK, Grandy RA, Lopez-Camacho C, Montecino M, van Wijnen AJ, Lian JB, Stein JL, Stein GS. 2014. Bookmarking target genes in mitosis: A shared epigenetic trait of phenotypic transcription factors and oncogenes. Cancer Res 74:420-425.